{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:31:07Z","timestamp":1790112667050,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Medullary thyroid cancer (MTC) is a rare malignant tumour of the parafollicular C-cells with an unpredictable clinical course and currently suboptimal diagnostic and therapeutic options, in particular in advanced disease. Overexpression of cholecystokinin-2 receptors (CCK2R) represents a promising avenue to diagnostic imaging and targeted therapy, ideally through a theranostic approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      A translational study (GRAN-T-MTC) conducted through a Phase I multicentre clinical trial of the indium-111 labelled CP04 ([\n                      <jats:sup>111<\/jats:sup>\n                      In]In-CP04), a CCK2R-seeking ligand was initiated with the goal of developing a theranostic compound. Patients with proven advanced\/metastatic MTC or short calcitonin doubling time were enrolled. A two-step concept was developed through the use of low- and high-peptide mass (10 and 50 \u03bcg, respectively) for safety assessment, with the higher peptide mass considered appropriate for therapeutic application. Gelofusine was co-infused in a randomized fashion in the second step for the evaluation of potential reduction of the absorbed dose to the kidneys. Imaging for the purpose of biodistribution, dosimetry evaluation, and diagnostic assessment were performed as well as pre-, peri-, and postprocedural clinical and biochemical assessment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixteen patients were enrolled. No serious adverse events after application of the compound at both peptide amounts were witnessed; transient tachycardia and flushing were observed in two patients. No changes in biochemistry and clinical status were observed on follow-up. Preliminary dosimetry assessment revealed the highest dose to urinary bladder, followed by the kidneys and stomach wall. The effective dose for 200 MBq of [\n                      <jats:sup>111<\/jats:sup>\n                      In]In-CP04 was estimated at 7\u00b13 mSv and 7\u00b11 mSv for 10 \u03bcg and 50 \u03bcg CP04, respectively. Administration of Gelofusine reduced the dose to the kidneys by 53%, resulting in the organ absorbed dose of 0.044\u00b10.019 mSv\/MBq. Projected absorbed dose to the kidneys with the use of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-CP04 was estimated at 0.9\u00b10.4 Gy\/7.4 GBq. [\n                      <jats:sup>111<\/jats:sup>\n                      In]In-CP04 scintigraphy was positive in 13 patients (detection rate of 81%) with superior diagnostic performance over conventional imaging.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In the present study, [\n                      <jats:sup>111<\/jats:sup>\n                      In]In-CP04 was shown to be a safe and effective radiopharmaceutical with promising theranostic characteristics for patients with advanced MTC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-022-05992-6","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T02:02:31Z","timestamp":1667613751000},"page":"892-907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["[111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial"],"prefix":"10.1007","volume":"50","author":[{"given":"Luka","family":"Lezaic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Anna","family":"Erba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Decristoforo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Zaletel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Mikolajczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Maecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodosia","family":"Maina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Konijnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Kolenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Trofimiuk-M\u00fcldner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elwira","family":"Przybylik-Mazurek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Virgolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alide C","family":"Fr\u00f6berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rangger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Di Santo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Skorkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Garnuszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Solnica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold A.","family":"Nock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Fedak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Gaweda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Hubalewska-Dydejczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,5]]},"reference":[{"key":"5992_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/jso.24954","volume":"117","author":"RW Randle","year":"2018","unstructured":"Randle RW, Bates MF, Schneider DF, et al. Survival in patients with medullary thyroid cancer after less than the recommended initial operation. J Surg Oncol. 2018;117:1211\u20136.","journal-title":"J Surg Oncol"},{"key":"5992_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.surg.2016.04.053","volume":"161","author":"RW Randle","year":"2017","unstructured":"Randle RW, Balentine CJ, Leverson GE, et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery. 2017;161:137\u201346.","journal-title":"Surgery"},{"key":"5992_CR3","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1634\/theoncologist.2013-0053","volume":"18","author":"M Roy","year":"2013","unstructured":"Roy M, Chen H, Sippel RS. Current understanding and management of medullary thyroid cancer. Oncologist. 2013;18:1093\u2013100.","journal-title":"Oncologist"},{"key":"5992_CR4","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/MNM.0b013e3283384587","volume":"31","author":"E Skoura","year":"2010","unstructured":"Skoura E, Rondogianni P, Alevizaki M, et al. Role of [(18)F]FDG-PET\/CT in the detection of occult recurrent medullary thyroid cancer. Nucl Med Commun. 2010;31:567\u201375.","journal-title":"Nucl Med Commun"},{"key":"5992_CR5","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","volume":"30","author":"S Filetti","year":"2019","unstructured":"Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol: Off J Euro Soc Med Oncol. 2019;30:1856\u201383.","journal-title":"Ann Oncol: Off J Euro Soc Med Oncol"},{"key":"5992_CR6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00259-009-1098-9","volume":"36","author":"AC Fr\u00f6berg","year":"2009","unstructured":"Fr\u00f6berg AC, de Jong M, Nock BA, et al. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:1265\u201372.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5992_CR7","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1007\/s00259-011-1818-9","volume":"38","author":"M Ocak","year":"2011","unstructured":"Ocak M, Helbok A, Rangger C, et al. Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. Eur J Nucl Med Mol Imaging. 2011;38:1426\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5992_CR8","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1021\/acs.bioconjchem.5b00187","volume":"26","author":"P Kolenc Peitl","year":"2015","unstructured":"Kolenc Peitl P, Tamma M, Kroselj M, et al. Stereochemistry of amino acid spacers determines the pharmacokinetics of (111)in-DOTA-minigastrin analogues for targeting the CCK2\/gastrin receptor. Bioconjug Chem. 2015;26:1113\u20139.","journal-title":"Bioconjug Chem"},{"key":"5992_CR9","first-page":"791","volume":"128","author":"PA Erba","year":"2018","unstructured":"Erba PA, Maecke H, Mikolajczak R, et al. A novel CCK2\/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study. Polish Arch Int Med. 2018;128:791\u20135.","journal-title":"Polish Arch Int Med"},{"key":"5992_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejps.2016.01.023","volume":"85","author":"D Pawlak","year":"2016","unstructured":"Pawlak D, Rangger C, Kolenc Peitl P, et al. From preclinical development to clinical application: kit formulation for radiolabelling the minigastrin analogue CP04 with in-111 for a first-in-human clinical trial. Eur J Pharm Sci: Off J Eur Fed Pharma Sci. 2016;85:1\u20139.","journal-title":"Eur J Pharm Sci: Off J Eur Fed Pharma Sci"},{"key":"5992_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejps.2016.05.011","volume":"91","author":"T Maina","year":"2016","unstructured":"Maina T, Konijnenberg MW, Kolenc Peitl P, et al. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)in-CP04 in medullary thyroid carcinoma patients. Eur J Pharma Sci: Off J Euro Fed Pharma Sci. 2016;91:236\u201342.","journal-title":"Eur J Pharma Sci: Off J Euro Fed Pharma Sci"},{"key":"5992_CR12","doi-asserted-by":"publisher","first-page":"R157","DOI":"10.1530\/ERC-15-0156","volume":"22","author":"P Trimboli","year":"2015","unstructured":"Trimboli P, Seregni E, Treglia G, et al. Procalcitonin for detecting medullary thyroid carcinoma: a systematic review. Endocr Relat Cancer. 2015;22:R157\u201364.","journal-title":"Endocr Relat Cancer"},{"key":"5992_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3803\/EnM.2018.33.2.204","volume":"33","author":"P Trimboli","year":"2018","unstructured":"Trimboli P, Giovanella L. Procalcitonin as marker of recurrent medullary thyroid carcinoma: a systematic review and meta-analysis. Endocrinol Metab (Seoul, Korea). 2018;33:204\u201310.","journal-title":"Endocrinol Metab (Seoul, Korea)"},{"key":"5992_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1177\/1724600817747518","volume":"33","author":"P Trimboli","year":"2018","unstructured":"Trimboli P, Lauretta R, Barnabei A, et al. Procalcitonin as a postoperative marker in the follow-up of patients affected by medullary thyroid carcinoma. Int J Biol Markers. 2018;33:156\u201360.","journal-title":"Int J Biol Markers"},{"key":"5992_CR15","first-page":"485","volume":"37","author":"A Kowalska","year":"2016","unstructured":"Kowalska A, Lizis-Kolus K, G\u0105sior-Perczak D, et al. Comparative assessment of calcitonin stimulation test using calcium gluconate and pentagastrin and the usefulness of procalcitonin basic and post-stimulation concentrations in the diagnosis of patients after surgery for medullary. Neuro Endocrinol Lett. 2016;37:485\u201390.","journal-title":"Neuro Endocrinol Lett"},{"key":"5992_CR16","doi-asserted-by":"publisher","first-page":"754565","DOI":"10.3389\/fendo.2021.754565","volume":"12","author":"S Censi","year":"2021","unstructured":"Censi S, Di Stefano M, Repaci A, et al. Basal and calcium-stimulated procalcitonin for the diagnosis of medullary thyroid cancers: lights and shadows. Front Endocrinol. 2021;12:754565.","journal-title":"Front Endocrinol"},{"key":"5992_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.2967\/jnumed.119.233031","volume":"61","author":"C Rottenburger","year":"2020","unstructured":"Rottenburger C, Nicolas GP, McDougall L, et al. Cholecystokinin 2 receptor agonist, 177Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma: results of the lumed phase 0a study. J Nucl Med. 2020;61:520\u20136.","journal-title":"J Nucl Med"},{"key":"5992_CR18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2174\/1874471011306020006","volume":"6","author":"K Slavikova","year":"2013","unstructured":"Slavikova K, Montravers F, Treglia G, et al. What is currently the best radiopharmaceutical for the hybrid PET\/CT detection of recurrent medullary thyroid carcinoma? Curr Radiopharm. 2013;6:96\u2013105.","journal-title":"Curr Radiopharm"},{"key":"5992_CR19","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1097\/RLU.0000000000002633","volume":"44","author":"M Terroir","year":"2019","unstructured":"Terroir M, Grimaldi S, Hartl D, et al. Parathyroid glands hyperplasias mimicking medullary thyroid carcinoma metastatic lymph nodes on 18F-DOPA PET\/CT. Clin Nucl Med. 2019;44:e497\u20138.","journal-title":"Clin Nucl Med"},{"key":"5992_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00259-019-04458-6","volume":"47","author":"L Giovanella","year":"2020","unstructured":"Giovanella L, Treglia G, Iakovou I, et al. EANM practice guideline for PET\/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2020;47:61\u201377.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5992_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/RLU.0000000000002940","volume":"45","author":"S-W Lee","year":"2020","unstructured":"Lee S-W, Shim SR, Jeong SY, et al. Comparison of 5 different PET radiopharmaceuticals for the detection of recurrent medullary thyroid carcinoma: a network meta-analysis. Clin Nucl Med. 2020;45:341\u20138.","journal-title":"Clin Nucl Med"},{"key":"5992_CR22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s12149-012-0602-7","volume":"26","author":"G Treglia","year":"2012","unstructured":"Treglia G, Giovannini E, Di Franco D, et al. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Ann Nucl Med. 2012;26:451\u201361.","journal-title":"Ann Nucl Med"},{"key":"5992_CR23","first-page":"362","volume":"16","author":"G Treglia","year":"2017","unstructured":"Treglia G, Tamburello A, Giovanella L. Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis. Hormones (Athens). 2017;16:362\u201372.","journal-title":"Hormones (Athens)"},{"key":"5992_CR24","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.acra.2012.05.008","volume":"19","author":"G Treglia","year":"2012","unstructured":"Treglia G, Cocciolillo F, Di Nardo F, et al. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. Acad Radiol. 2012;19:1290\u20139.","journal-title":"Acad Radiol"},{"key":"5992_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40644-019-0263-z","volume":"19","author":"D Puhr-Westerheide","year":"2019","unstructured":"Puhr-Westerheide D, Cyran CC, Sargsyan-Bergmann J, et al. The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET\/CT for liver staging in medullary thyroid carcinoma. Cancer Imaging. 2019;19:73.","journal-title":"Cancer Imaging"},{"key":"5992_CR26","doi-asserted-by":"publisher","first-page":"5776","DOI":"10.3390\/cancers13225776","volume":"13","author":"E von Guggenberg","year":"2021","unstructured":"von Guggenberg E, Kolenc P, Rottenburger C, et al. Update on preclinical development and clinical translation of cholecystokinin-2 receptor targeting radiopharmaceuticals. Cancers. 2021;13:5776.","journal-title":"Cancers"},{"key":"5992_CR27","first-page":"134","volume":"60","author":"C Rottenburger","year":"2021","unstructured":"Rottenburger C, Nicolas G, McDougall L, et al. The CCK-2 receptor agonist Lu-177-PP-F11N for PRRT of medullary thyroid cancer \u2013 recent results of the phase 1 \u201cLUMED\u201d study. Nuklearmedizin. 2021;60:134.","journal-title":"Nuklearmedizin"},{"key":"5992_CR28","first-page":"708","volume":"44","author":"M Gabriel","year":"2003","unstructured":"Gabriel M, Decristoforo C, Donnemiller E, et al. An intrapatient comparison of 99mTc-EDDA\/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med: Off Publ, Soc Nucl Med. 2003;44:708\u201316.","journal-title":"J Nucl Med: Off Publ, Soc Nucl Med"},{"key":"5992_CR29","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00259-007-0450-1","volume":"34","author":"I Buchmann","year":"2007","unstructured":"Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617\u201326.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5992_CR30","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2967\/jnumed.109.066134","volume":"51","author":"R Srirajaskanthan","year":"2010","unstructured":"Srirajaskanthan R, Kayani I, Quigley AM, et al. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010;51:875\u201382.","journal-title":"J Nucl Med"},{"key":"5992_CR31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s13139-015-0356-y","volume":"49","author":"I Lee","year":"2015","unstructured":"Lee I, Paeng JC, Lee SJ, et al. Comparison of diagnostic sensitivity and quantitative indices between (68)Ga-DOTATOC PET\/CT and (111)in-pentetreotide SPECT\/CT in neuroendocrine tumors: a preliminary report. Nucl Med Mol Imaging. 2015;49:284\u201390.","journal-title":"Nucl Med Mol Imaging"},{"key":"5992_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5603\/EP.2016.0010","volume":"67","author":"J Kunikowska","year":"2016","unstructured":"Kunikowska J, Ziemnicka K, Pawlak D, et al. Medullary thyroid carcinoma - PET\/CT imaging with 68Ga-labelled gastrin and somatostatin analogues. Endokrynol Pol. 2016;67:68\u201371.","journal-title":"Endokrynol Pol"},{"key":"5992_CR33","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00259-020-04963-z","volume":"48","author":"C Uprimny","year":"2021","unstructured":"Uprimny C, von Guggenberg E, Svirydenka A, et al. Comparison of PET\/CT imaging with [18F]FDOPA and cholecystokinin-2 receptor targeting [68Ga]Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:935\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5992_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1089\/thy.2020.0674","volume":"31","author":"F Castinetti","year":"2021","unstructured":"Castinetti F, Ta\u00efeb D. Positron emission tomography imaging in medullary thyroid carcinoma: time for reappraisal? Thyroid\u202f: Off J Am Thyroid Assoc. 2021;31:151\u20135.","journal-title":"Thyroid : Off J Am Thyroid Assoc"},{"key":"5992_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000509457","volume":"10","author":"ZA Efstathiadou","year":"2021","unstructured":"Efstathiadou ZA, Tsentidis C, Bargiota A, et al. Benefits and limitations of TKIs in patients with medullary thyroid cancer: a systematic review and meta-analysis. Eur Thyroid J. 2021;10:125\u201339.","journal-title":"Eur Thyroid J"},{"key":"5992_CR36","first-page":"e4903","volume":"106","author":"AR Hayes","year":"2021","unstructured":"Hayes AR, Crawford A, Al Riyami K, et al. Metastatic medullary thyroid cancer: the role of 68Gallium-DOTA-somatostatin analogue PET\/CT and peptide receptor radionuclide therapy. J Clin Endocrinol Metab. 2021;106:e4903\u201316.","journal-title":"J Clin Endocrinol Metab"},{"key":"5992_CR37","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.3390\/jcm9113507","volume":"9","author":"E Grossrubatscher","year":"2020","unstructured":"Grossrubatscher E, Fanciulli G, Pes L, et al. Advances in the management of medullary thyroid carcinoma: focus on peptide receptor radionuclide therapy. J Clin Med. 2020;9:3507.","journal-title":"J Clin Med"},{"key":"5992_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/ph12010013","volume":"12","author":"M Klingler","year":"2019","unstructured":"Klingler M, Rangger C, Summer D, et al. Cholecystokinin-2 receptor targeting with novel C-terminally stabilized HYNIC-minigastrin analogs radiolabeled with technetium-99m. Pharmaceuticals (Basel, Switzerland). 2019;12:13.","journal-title":"Pharmaceuticals (Basel, Switzerland)"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05992-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-05992-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05992-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T01:05:45Z","timestamp":1674090345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-05992-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,5]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["5992"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-05992-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,5]]},"assertion":[{"value":"30 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}